<- Go Home

BICO Group AB (publ)

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Market Cap

SEK 1.7B

Volume

259.6K

Cash and Equivalents

SEK 627.6M

EBITDA

-SEK 80.3M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

SEK 825.8M

Profit Margin

54.90%

52 Week High

SEK 25.42

52 Week Low

SEK 12.94

Dividend

N/A

Price / Book Value

1.08

Price / Earnings

-1.26

Price / Tangible Book Value

5.64

Enterprise Value

SEK 1.7B

Enterprise Value / EBITDA

-74.93

Operating Income

-SEK 182.6M

Return on Equity

66.26%

Return on Assets

-3.09

Cash and Short Term Investments

SEK 627.6M

Debt

SEK 686.7M

Equity

SEK 1.6B

Revenue

SEK 1.5B

Unlevered FCF

SEK 455.1M

Sector

Life Sciences Tools and Services

Category

N/A

Company Stock Pitches